Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Institute for Neurodegenerative Disorders Molecular NeuroImaging National Institutes of Health (NIH) |
---|---|
Information provided by: | Institute for Neurodegenerative Disorders |
ClinicalTrials.gov Identifier: | NCT00132626 |
This study assesses dopamine transporter density using single photon emission computed tomography (SPECT) brain imaging with an investigational radiopharmaceutical, [123I]ß-CIT, in research participants with Parkinson's disease.
Condition | Intervention | Phase |
---|---|---|
Parkinson's Disease Parkinsonian Syndrome |
Procedure: [123I]ß-CIT and SPECT imaging |
Phase II |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism |
Estimated Enrollment: | 500 |
Study Start Date: | September 1992 |
Estimated Study Completion Date: | August 2005 |
The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New Haven, Connecticut. The imaging procedure occurs over a two day period.
After a screening visit, including review of the potential subject's neurological history and a thorough neurologic exam, subjects are injected with [123I]ß CIT, an investigational radioactive material that localizes in the brain.
Twenty-four hours later study participants return to the Institute for Neurodegenerative Disorders where an investigational scanning procedure is used to obtain SPECT (single photon emission computed tomography) images of the brain.
Ages Eligible for Study: | 35 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | Dopamine Transporter Imaging |
Study First Received: | August 18, 2005 |
Last Updated: | February 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00132626 History of Changes |
Health Authority: | United States: Food and Drug Administration |
parkinson diagnosis |
Ganglion Cysts Movement Disorders Parkinson Disease Basal Ganglia Diseases |
Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases |
Pathologic Processes Disease Movement Disorders Parkinson Disease Syndrome Nervous System Diseases |
Basal Ganglia Diseases Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases |